Össur: Solid start to new strategic era - ABG

Solid Q1, in line with consensus
Strategic case remains unchanged after recent CMD
No estimate changes, fair value remains at DKK 24-54


Sales growth across all segments and regions

Q1'23 saw reported revenues of USD 181m (0% vs. company-collected consensus), corresponding to reported growth of 7% across the group. Growth was recorded in all segments and regions, but primarily driven by APAC, which was up 12% (but it only accounts for ~9% of group sales) and Americas up 12% (~48% of group sales). On the segment side, prosthetics was up 12%, with sales of USD 91m (beating cons by 2%). The growth was also helped by price increases, with the company mentioning that most of the reimbursement systems it works with have increased prices from zero percent to inflation-related price increases.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2023/4/ossur---solid-start-to-new-strategic-era-/